Massive drug search uncovers infinitesimal molecule that kills cancers while sparing immune cells

by Delthia Ricks , Medical XpressN6F11 suppresses the growth of human PDAC. (A) PANC1 cells were pretreated with DMSO or N6F11 (5 µM) for 12 hours. (B) MiaPACA2 cells were pretreated with DMSO or N6F1

Updated on: December 30,2023

Massive drug search uncovers infinitesimal molecule that kills cancers while sparing immune cells

by Delthia Ricks , Medical XpressN6F11 suppresses the growth of human PDAC. (A) PANC1 cells were pretreated with DMSO or N6F11 (5 µM) for 12 hours. (B) MiaPACA2 cells were pretreated with DMSO or N6F1

Updated on:December 30,2023

Treatment for recurrent uterine cancer advances to next research phase

by Yale Cancer Center/Smilow Cancer HospitalCredit: Pixabay/CC0 Public DomainThe latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanc

Updated on: August 27,2024

Treatment for recurrent uterine cancer advances to next research phase

by Yale Cancer Center/Smilow Cancer HospitalCredit: Pixabay/CC0 Public DomainThe latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanc

Updated on:August 27,2024

Estrogen-negative cancers respond to anti-estrogenic therapies, study shows

byHokkaido UniversityCredit: Nabeel KajiharaAnti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor t

Updated on: January 22,2024

Estrogen-negative cancers respond to anti-estrogenic therapies, study shows

byHokkaido UniversityCredit: Nabeel KajiharaAnti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor t

Updated on:January 22,2024

A predictive biomarker of response to therapy in patients with microsatellite stable metastatic colorectal cancer

by Vall d'Hebron Institute of OncologyA total of 166 patients with mCRCBRAF-V600Ewere included in the study from discovery (n = 46), validation (n = 52) and control (n = 68) cohorts. WES of

Updated on: January 08,2024

A predictive biomarker of response to therapy in patients with microsatellite stable metastatic colorectal cancer

by Vall d'Hebron Institute of OncologyA total of 166 patients with mCRCBRAF-V600Ewere included in the study from discovery (n = 46), validation (n = 52) and control (n = 68) cohorts. WES of

Updated on:January 08,2024

Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled &quot

Updated on: May 07,2024

Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma

by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled &quot

Updated on:May 07,2024

Are fighter pilots at greater risk for prostate cancer? The Air Force is now asking

by Tara Copp And Shirsho Dasgupta, Mcclatchy Washington BureauCredit: CC0 Public DomainThe Air Force has begun to look at whether there's increased risk for prostate cancer among its fighter pilot

Updated on: April 18,2024

Are fighter pilots at greater risk for prostate cancer? The Air Force is now asking

by Tara Copp And Shirsho Dasgupta, Mcclatchy Washington BureauCredit: CC0 Public DomainThe Air Force has begun to look at whether there's increased risk for prostate cancer among its fighter pilot

Updated on:April 18,2024

12.8 percent of unique prescribers prescribed topical antifungals in 2021

by Elana GotkineIn 2021, 12.8 percent of unique prescribers in Medicare Part D prescribed topical antifungals, with about 6.5 million topical antifungal prescriptions filled, at a total cost of $231 m

Updated on: March 22,2024

12.8 percent of unique prescribers prescribed topical antifungals in 2021

by Elana GotkineIn 2021, 12.8 percent of unique prescribers in Medicare Part D prescribed topical antifungals, with about 6.5 million topical antifungal prescriptions filled, at a total cost of $231 m

Updated on:March 22,2024

A breast cancer drug, susceptible to resistance, can be restored to effectiveness, researchers demonstrate

by Leslie Cantu,Medical University of South CarolinaCredit: Pixabay/CC0 Public DomainIn a new paperpublishedinCancer Research, researchers at MUSC Hollings Cancer Center have s

Updated on: May 06,2024

A breast cancer drug, susceptible to resistance, can be restored to effectiveness, researchers demonstrate

by Leslie Cantu,Medical University of South CarolinaCredit: Pixabay/CC0 Public DomainIn a new paperpublishedinCancer Research, researchers at MUSC Hollings Cancer Center have s

Updated on:May 06,2024

Exploring mini-labs as an alternative to animal testing for evaluating radiopharmaceuticals

byHelmholtz Association of German Research CentresMPS layout; red—media circuit with integrated pump; blue—pneumatic connectors; yellow—microwells for organoids; green—LUER-connectors). Credit:&

Updated on: January 07,2024

Exploring mini-labs as an alternative to animal testing for evaluating radiopharmaceuticals

byHelmholtz Association of German Research CentresMPS layout; red—media circuit with integrated pump; blue—pneumatic connectors; yellow—microwells for organoids; green—LUER-connectors). Credit:&

Updated on:January 07,2024

New genetic test for pancreatic cancer outperforms current guidelines

by University of PittsburghCredit: Pixabay/CC0 Public DomainA molecular test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, according to a large, mul

Updated on: January 30,2024

New genetic test for pancreatic cancer outperforms current guidelines

by University of PittsburghCredit: Pixabay/CC0 Public DomainA molecular test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, according to a large, mul

Updated on:January 30,2024

Avelumab plus axitinib significantly improve progression-free survival in untreated renal cell carcinoma

byEuropean Society for Medical OncologyCredit: CC0 Public DomainA combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improv

Updated on: December 18,2023

Avelumab plus axitinib significantly improve progression-free survival in untreated renal cell carcinoma

byEuropean Society for Medical OncologyCredit: CC0 Public DomainA combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improv

Updated on:December 18,2023

New hybrid treatment forces cancer cells to starve

by Greg Williams,NYU Langone HealthCredit: Unsplash/CC0 Public DomainThe combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.The wor

Updated on: January 26,2024

New hybrid treatment forces cancer cells to starve

by Greg Williams,NYU Langone HealthCredit: Unsplash/CC0 Public DomainThe combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.The wor

Updated on:January 26,2024